#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Motivational Deficits in Schizophrenia Are Associated with Reduced Differentiation between Gain and Loss-Avoidance Feedback in the Striatum Background The current study was designed to test the hypothesis that motivational deficits in schizophrenia (SZ) are tied to a reduced ability to differentially signal gains and instances of loss-avoidance in the brain, leading to reduced ability to form adaptive representations of expected value.
1-1	0-12	Motivational	_
1-2	13-21	Deficits	_
1-3	22-24	in	_
1-4	25-38	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-5	39-42	Are	_
1-6	43-53	Associated	_
1-7	54-58	with	_
1-8	59-66	Reduced	_
1-9	67-82	Differentiation	_
1-10	83-90	between	_
1-11	91-95	Gain	_
1-12	96-99	and	_
1-13	100-114	Loss-Avoidance	_
1-14	115-123	Feedback	_
1-15	124-126	in	_
1-16	127-130	the	_
1-17	131-139	Striatum	_
1-18	140-150	Background	_
1-19	151-154	The	_
1-20	155-162	current	_
1-21	163-168	study	_
1-22	169-172	was	_
1-23	173-181	designed	_
1-24	182-184	to	_
1-25	185-189	test	_
1-26	190-193	the	_
1-27	194-204	hypothesis	_
1-28	205-209	that	_
1-29	210-222	motivational	_
1-30	223-231	deficits	_
1-31	232-234	in	_
1-32	235-248	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-33	249-250	(	_
1-34	251-253	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
1-35	254-255	)	_
1-36	256-259	are	_
1-37	260-264	tied	_
1-38	265-267	to	_
1-39	268-269	a	_
1-40	270-277	reduced	_
1-41	278-285	ability	_
1-42	286-288	to	_
1-43	289-303	differentially	_
1-44	304-310	signal	_
1-45	311-316	gains	_
1-46	317-320	and	_
1-47	321-330	instances	_
1-48	331-333	of	_
1-49	334-348	loss-avoidance	_
1-50	349-351	in	_
1-51	352-355	the	_
1-52	356-361	brain	_
1-53	362-363	,	_
1-54	364-371	leading	_
1-55	372-374	to	_
1-56	375-382	reduced	_
1-57	383-390	ability	_
1-58	391-393	to	_
1-59	394-398	form	_
1-60	399-407	adaptive	_
1-61	408-423	representations	_
1-62	424-426	of	_
1-63	427-435	expected	_
1-64	436-441	value	_
1-65	442-443	.	_

Text=Methods We administered a reinforcement learning paradigm to 27 medicated SZ patients and 27 controls, in which participants learned three probabilistic discriminations.
2-1	444-451	Methods	_
2-2	452-454	We	_
2-3	455-467	administered	_
2-4	468-469	a	_
2-5	470-483	reinforcement	_
2-6	484-492	learning	_
2-7	493-501	paradigm	_
2-8	502-504	to	_
2-9	505-507	27	_
2-10	508-517	medicated	http://maven.renci.org/NeuroBridge/neurobridge#Medicated
2-11	518-520	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-12	521-529	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-13	530-533	and	_
2-14	534-536	27	_
2-15	537-545	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
2-16	546-547	,	_
2-17	548-550	in	_
2-18	551-556	which	_
2-19	557-569	participants	_
2-20	570-577	learned	_
2-21	578-583	three	_
2-22	584-597	probabilistic	_
2-23	598-613	discriminations	_
2-24	614-615	.	_

Text=In regions of interest in reward networks identified a priori, we examined contrasts between trial-types with different expected values (Expected Gain – Non-monetary, e.g.
3-1	616-618	In	_
3-2	619-626	regions	_
3-3	627-629	of	_
3-4	630-638	interest	_
3-5	639-641	in	_
3-6	642-648	reward	_
3-7	649-657	networks	_
3-8	658-668	identified	_
3-9	669-670	a	_
3-10	671-677	priori	_
3-11	678-679	,	_
3-12	680-682	we	_
3-13	683-691	examined	_
3-14	692-701	contrasts	_
3-15	702-709	between	_
3-16	710-721	trial-types	_
3-17	722-726	with	_
3-18	727-736	different	_
3-19	737-745	expected	_
3-20	746-752	values	_
3-21	753-754	(	_
3-22	755-763	Expected	_
3-23	764-768	Gain	_
3-24	769-770	–	_
3-25	771-783	Non-monetary	_
3-26	784-785	,	_
3-27	786-789	e.g	_
3-28	790-791	.	_

Text=), and between outcomes with the same prediction error valence but different experienced values (Gain – Loss-avoidance outcome, Miss – Loss outcome, e.g .).
4-1	792-793	)	_
4-2	794-795	,	_
4-3	796-799	and	_
4-4	800-807	between	_
4-5	808-816	outcomes	_
4-6	817-821	with	_
4-7	822-825	the	_
4-8	826-830	same	_
4-9	831-841	prediction	_
4-10	842-847	error	_
4-11	848-855	valence	_
4-12	856-859	but	_
4-13	860-869	different	_
4-14	870-881	experienced	_
4-15	882-888	values	_
4-16	889-890	(	_
4-17	891-895	Gain	_
4-18	896-897	–	_
4-19	898-912	Loss-avoidance	_
4-20	913-920	outcome	_
4-21	921-922	,	_
4-22	923-927	Miss	_
4-23	928-929	–	_
4-24	930-934	Loss	_
4-25	935-942	outcome	_
4-26	943-944	,	_
4-27	945-948	e.g	_
4-28	949-950	.	_
4-29	951-952	)	_
4-30	953-954	.	_

Text=Results Both whole-brain and regions-of-interest analyses revealed that schizophrenia patients showed reduced differentiation between Gain and Loss-avoidance outcomes in dorsal anterior cingulate cortex and bilateral anterior insula.
5-1	955-962	Results	_
5-2	963-967	Both	_
5-3	968-979	whole-brain	_
5-4	980-983	and	_
5-5	984-1003	regions-of-interest	_
5-6	1004-1012	analyses	_
5-7	1013-1021	revealed	_
5-8	1022-1026	that	_
5-9	1027-1040	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-10	1041-1049	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-11	1050-1056	showed	_
5-12	1057-1064	reduced	_
5-13	1065-1080	differentiation	_
5-14	1081-1088	between	_
5-15	1089-1093	Gain	_
5-16	1094-1097	and	_
5-17	1098-1112	Loss-avoidance	_
5-18	1113-1121	outcomes	_
5-19	1122-1124	in	_
5-20	1125-1131	dorsal	_
5-21	1132-1140	anterior	_
5-22	1141-1150	cingulate	_
5-23	1151-1157	cortex	_
5-24	1158-1161	and	_
5-25	1162-1171	bilateral	_
5-26	1172-1180	anterior	_
5-27	1181-1187	insula	_
5-28	1188-1189	.	_

Text=That is, SZ patients showed reduced contrasts between positive prediction errors of different objective values in these areas.
6-1	1190-1194	That	_
6-2	1195-1197	is	_
6-3	1198-1199	,	_
6-4	1200-1202	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
6-5	1203-1211	patients	_
6-6	1212-1218	showed	_
6-7	1219-1226	reduced	_
6-8	1227-1236	contrasts	_
6-9	1237-1244	between	_
6-10	1245-1253	positive	_
6-11	1254-1264	prediction	_
6-12	1265-1271	errors	_
6-13	1272-1274	of	_
6-14	1275-1284	different	_
6-15	1285-1294	objective	_
6-16	1295-1301	values	_
6-17	1302-1304	in	_
6-18	1305-1310	these	_
6-19	1311-1316	areas	_
6-20	1317-1318	.	_

Text=Furthermore, we observed significant correlations between [Gain – Loss-avoidance outcome] contrasts in ventral striatum and ratings for Avolition/Anhedonia, and between [Expected Gain – Non-monetary] contrasts in ventral striatum and ventromedial prefrontal cortex.
7-1	1319-1330	Furthermore	_
7-2	1331-1332	,	_
7-3	1333-1335	we	_
7-4	1336-1344	observed	_
7-5	1345-1356	significant	_
7-6	1357-1369	correlations	_
7-7	1370-1377	between	_
7-8	1378-1379	[	_
7-9	1380-1384	Gain	_
7-10	1385-1386	–	_
7-11	1387-1401	Loss-avoidance	_
7-12	1402-1409	outcome	_
7-13	1410-1411	]	_
7-14	1412-1421	contrasts	_
7-15	1422-1424	in	_
7-16	1425-1432	ventral	_
7-17	1433-1441	striatum	_
7-18	1442-1445	and	_
7-19	1446-1453	ratings	_
7-20	1454-1457	for	_
7-21	1458-1477	Avolition/Anhedonia	_
7-22	1478-1479	,	_
7-23	1480-1483	and	_
7-24	1484-1491	between	_
7-25	1492-1493	[	_
7-26	1494-1502	Expected	_
7-27	1503-1507	Gain	_
7-28	1508-1509	–	_
7-29	1510-1522	Non-monetary	_
7-30	1523-1524	]	_
7-31	1525-1534	contrasts	_
7-32	1535-1537	in	_
7-33	1538-1545	ventral	_
7-34	1546-1554	striatum	_
7-35	1555-1558	and	_
7-36	1559-1571	ventromedial	_
7-37	1572-1582	prefrontal	_
7-38	1583-1589	cortex	_
7-39	1590-1591	.	_

Text=Conclusions These results provide further evidence for intact prediction error signaling in medicated schizophrenia patients, especially with regard to loss-avoidance.
8-1	1592-1603	Conclusions	_
8-2	1604-1609	These	_
8-3	1610-1617	results	_
8-4	1618-1625	provide	_
8-5	1626-1633	further	_
8-6	1634-1642	evidence	_
8-7	1643-1646	for	_
8-8	1647-1653	intact	_
8-9	1654-1664	prediction	_
8-10	1665-1670	error	_
8-11	1671-1680	signaling	_
8-12	1681-1683	in	_
8-13	1684-1693	medicated	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-14	1694-1707	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-15	1708-1716	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-16	1717-1718	,	_
8-17	1719-1729	especially	_
8-18	1730-1734	with	_
8-19	1735-1741	regard	_
8-20	1742-1744	to	_
8-21	1745-1759	loss-avoidance	_
8-22	1760-1761	.	_

Text=By contrast components of frontostriatal circuits appear to show reduced sensitivity to the absolute valence of expected and experienced outcomes, suggesting a mechanism by which motivational deficits may emerge.
9-1	1762-1764	By	_
9-2	1765-1773	contrast	_
9-3	1774-1784	components	_
9-4	1785-1787	of	_
9-5	1788-1802	frontostriatal	_
9-6	1803-1811	circuits	_
9-7	1812-1818	appear	_
9-8	1819-1821	to	_
9-9	1822-1826	show	_
9-10	1827-1834	reduced	_
9-11	1835-1846	sensitivity	_
9-12	1847-1849	to	_
9-13	1850-1853	the	_
9-14	1854-1862	absolute	_
9-15	1863-1870	valence	_
9-16	1871-1873	of	_
9-17	1874-1882	expected	_
9-18	1883-1886	and	_
9-19	1887-1898	experienced	_
9-20	1899-1907	outcomes	_
9-21	1908-1909	,	_
9-22	1910-1920	suggesting	_
9-23	1921-1922	a	_
9-24	1923-1932	mechanism	_
9-25	1933-1935	by	_
9-26	1936-1941	which	_
9-27	1942-1954	motivational	_
9-28	1955-1963	deficits	_
9-29	1964-1967	may	_
9-30	1968-1974	emerge	_
9-31	1975-1976	.	_

Text=Methods and Materials General Procedures Twenty-nine SZ patients and 28 healthy volunteers, matched on demographic characteristics and smoking status, successfully completed an RL task in the MRI scanner (see Supplementary Methods for details of screening procedures).
10-1	1977-1984	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-2	1985-1988	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-3	1989-1998	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-4	1999-2006	General	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-5	2007-2017	Procedures	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-6	2018-2029	Twenty-nine	_
10-7	2030-2032	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-8	2033-2041	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-9	2042-2045	and	_
10-10	2046-2048	28	_
10-11	2049-2056	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-12	2057-2067	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-13	2068-2069	,	_
10-14	2070-2077	matched	_
10-15	2078-2080	on	_
10-16	2081-2092	demographic	_
10-17	2093-2108	characteristics	_
10-18	2109-2112	and	_
10-19	2113-2120	smoking	_
10-20	2121-2127	status	_
10-21	2128-2129	,	_
10-22	2130-2142	successfully	_
10-23	2143-2152	completed	_
10-24	2153-2155	an	_
10-25	2156-2158	RL	_
10-26	2159-2163	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
10-27	2164-2166	in	_
10-28	2167-2170	the	_
10-29	2171-2174	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
10-30	2175-2182	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
10-31	2183-2184	(	_
10-32	2185-2188	see	_
10-33	2189-2202	Supplementary	_
10-34	2203-2210	Methods	_
10-35	2211-2214	for	_
10-36	2215-2222	details	_
10-37	2223-2225	of	_
10-38	2226-2235	screening	_
10-39	2236-2246	procedures	_
10-40	2247-2248	)	_
10-41	2249-2250	.	_

Text=All patients except one were medicated with antipsychotic drugs, with all those medicated being on stable antipsychotic medication regimens (no changes for four weeks).
11-1	2251-2254	All	_
11-2	2255-2263	patients	_
11-3	2264-2270	except	_
11-4	2271-2274	one	_
11-5	2275-2279	were	_
11-6	2280-2289	medicated	_
11-7	2290-2294	with	_
11-8	2295-2308	antipsychotic	_
11-9	2309-2314	drugs	_
11-10	2315-2316	,	_
11-11	2317-2321	with	_
11-12	2322-2325	all	_
11-13	2326-2331	those	_
11-14	2332-2341	medicated	_
11-15	2342-2347	being	_
11-16	2348-2350	on	_
11-17	2351-2357	stable	_
11-18	2358-2371	antipsychotic	_
11-19	2372-2382	medication	_
11-20	2383-2391	regimens	_
11-21	2392-2393	(	_
11-22	2394-2396	no	_
11-23	2397-2404	changes	_
11-24	2405-2408	for	_
11-25	2409-2413	four	_
11-26	2414-2419	weeks	_
11-27	2420-2421	)	_
11-28	2422-2423	.	_

Text=Outside of the MRI scanner, cognitive function was assessed using three standard measures: the Wechsler Abbreviated Scale of Intelligence (WASI; 23), the Wechsler Test of Adult Reading (WTAR; 24), and the MATRICS battery.
12-1	2424-2431	Outside	_
12-2	2432-2434	of	_
12-3	2435-2438	the	_
12-4	2439-2442	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
12-5	2443-2450	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
12-6	2451-2452	,	_
12-7	2453-2462	cognitive	_
12-8	2463-2471	function	_
12-9	2472-2475	was	_
12-10	2476-2484	assessed	_
12-11	2485-2490	using	_
12-12	2491-2496	three	_
12-13	2497-2505	standard	_
12-14	2506-2514	measures	_
12-15	2515-2516	:	_
12-16	2517-2520	the	_
12-17	2521-2529	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
12-18	2530-2541	Abbreviated	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
12-19	2542-2547	Scale	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
12-20	2548-2550	of	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
12-21	2551-2563	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
12-22	2564-2565	(	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
12-23	2566-2570	WASI	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
12-24	2571-2572	;	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
12-25	2573-2575	23	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
12-26	2576-2577	)	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
12-27	2578-2579	,	_
12-28	2580-2583	the	_
12-29	2584-2592	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
12-30	2593-2597	Test	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
12-31	2598-2600	of	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
12-32	2601-2606	Adult	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
12-33	2607-2614	Reading	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
12-34	2615-2616	(	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
12-35	2617-2621	WTAR	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
12-36	2622-2623	;	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
12-37	2624-2626	24	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
12-38	2627-2628	)	_
12-39	2629-2630	,	_
12-40	2631-2634	and	_
12-41	2635-2638	the	_
12-42	2639-2646	MATRICS	http://maven.renci.org/NeuroBridge/neurobridge#PediatricSleepQuestionnaire
12-43	2647-2654	battery	_
12-44	2655-2656	.	_

Text=Standard symptom ratings were obtained for all patients using the Scale for the Assessment of Negative Symptoms (SANS; 26), the Brief Psychiatric Rating Scale (BPRS; 27), and the Calgary Depression Scale (CDS; 28).
13-1	2657-2665	Standard	_
13-2	2666-2673	symptom	_
13-3	2674-2681	ratings	_
13-4	2682-2686	were	_
13-5	2687-2695	obtained	_
13-6	2696-2699	for	_
13-7	2700-2703	all	_
13-8	2704-2712	patients	_
13-9	2713-2718	using	_
13-10	2719-2722	the	_
13-11	2723-2728	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
13-12	2729-2732	for	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
13-13	2733-2736	the	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
13-14	2737-2747	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
13-15	2748-2750	of	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
13-16	2751-2759	Negative	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
13-17	2760-2768	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
13-18	2769-2770	(	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
13-19	2771-2775	SANS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
13-20	2776-2777	;	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
13-21	2778-2780	26	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
13-22	2781-2782	)	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
13-23	2783-2784	,	_
13-24	2785-2788	the	_
13-25	2789-2794	Brief	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
13-26	2795-2806	Psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
13-27	2807-2813	Rating	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
13-28	2814-2819	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
13-29	2820-2821	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
13-30	2822-2826	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
13-31	2827-2828	;	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
13-32	2829-2831	27	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
13-33	2832-2833	)	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
13-34	2834-2835	,	_
13-35	2836-2839	and	_
13-36	2840-2843	the	_
13-37	2844-2851	Calgary	http://maven.renci.org/NeuroBridge/neurobridge#CalgaryDepressionScale
13-38	2852-2862	Depression	http://maven.renci.org/NeuroBridge/neurobridge#CalgaryDepressionScale
13-39	2863-2868	Scale	http://maven.renci.org/NeuroBridge/neurobridge#CalgaryDepressionScale
13-40	2869-2870	(	http://maven.renci.org/NeuroBridge/neurobridge#CalgaryDepressionScale
13-41	2871-2874	CDS	_
13-42	2875-2876	;	_
13-43	2877-2879	28	_
13-44	2880-2881	)	_
13-45	2882-2883	.	_

Text=Acquisition of behavioral and neuroimaging data Participants performed 240 trials (average length: 6 s) of a version of the Gain vs. Loss-avoidance probabilistic RL task similar to that used in our prior work (19; Table 1).
14-1	2884-2895	Acquisition	_
14-2	2896-2898	of	_
14-3	2899-2909	behavioral	_
14-4	2910-2913	and	_
14-5	2914-2926	neuroimaging	_
14-6	2927-2931	data	_
14-7	2932-2944	Participants	_
14-8	2945-2954	performed	_
14-9	2955-2958	240	_
14-10	2959-2965	trials	_
14-11	2966-2967	(	_
14-12	2968-2975	average	_
14-13	2976-2982	length	_
14-14	2983-2984	:	_
14-15	2985-2986	6	_
14-16	2987-2988	s	_
14-17	2989-2990	)	_
14-18	2991-2993	of	_
14-19	2994-2995	a	_
14-20	2996-3003	version	http://maven.renci.org/NeuroBridge/neurobridge#DementiaoftheLewyBodyType
14-21	3004-3006	of	http://maven.renci.org/NeuroBridge/neurobridge#DementiaoftheLewyBodyType
14-22	3007-3010	the	http://maven.renci.org/NeuroBridge/neurobridge#DementiaoftheLewyBodyType
14-23	3011-3015	Gain	_
14-24	3016-3019	vs.	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
14-25	3020-3034	Loss-avoidance	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
14-26	3035-3048	probabilistic	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
14-27	3049-3051	RL	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
14-28	3052-3056	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
14-29	3057-3064	similar	_
14-30	3065-3067	to	_
14-31	3068-3072	that	_
14-32	3073-3077	used	_
14-33	3078-3080	in	_
14-34	3081-3084	our	_
14-35	3085-3090	prior	_
14-36	3091-3095	work	_
14-37	3096-3097	(	_
14-38	3098-3100	19	_
14-39	3101-3102	;	_
14-40	3103-3108	Table	_
14-41	3109-3110	1	_
14-42	3111-3112	)	_
14-43	3113-3114	.	_

Text=Functional MRI data were acquired simultaneous with task performance, in four EPI scanning runs, each lasting ≈7 minutes (with lead time) and involving the acquisition of 191 whole-brain functional EPI images (for measurement of T2 * -weighted BOLD effects) using a 3-T Siemens Trio scanner (Erlangen, Germany; 81 2-mm axial slices; 128 × 128 matrix; FOV = 22 × 22 cm; TR = 2 s; see Supplementary Methods for additional scanning parameters).
15-1	3115-3125	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
15-2	3126-3129	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
15-3	3130-3134	data	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
15-4	3135-3139	were	_
15-5	3140-3148	acquired	_
15-6	3149-3161	simultaneous	_
15-7	3162-3166	with	_
15-8	3167-3171	task	_
15-9	3172-3183	performance	_
15-10	3184-3185	,	_
15-11	3186-3188	in	_
15-12	3189-3193	four	_
15-13	3194-3197	EPI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
15-14	3198-3206	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
15-15	3207-3211	runs	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
15-16	3212-3213	,	_
15-17	3214-3218	each	_
15-18	3219-3226	lasting	_
15-19	3227-3229	≈7	_
15-20	3230-3237	minutes	_
15-21	3238-3239	(	_
15-22	3240-3244	with	_
15-23	3245-3249	lead	_
15-24	3250-3254	time	_
15-25	3255-3256	)	_
15-26	3257-3260	and	_
15-27	3261-3270	involving	_
15-28	3271-3274	the	_
15-29	3275-3286	acquisition	_
15-30	3287-3289	of	_
15-31	3290-3293	191	_
15-32	3294-3305	whole-brain	_
15-33	3306-3316	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
15-34	3317-3320	EPI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
15-35	3321-3327	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
15-36	3328-3329	(	_
15-37	3330-3333	for	_
15-38	3334-3345	measurement	_
15-39	3346-3348	of	_
15-40	3349-3351	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
15-41	3352-3353	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
15-42	3354-3363	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
15-43	3364-3368	BOLD	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
15-44	3369-3376	effects	_
15-45	3377-3378	)	_
15-46	3379-3384	using	_
15-47	3385-3386	a	_
15-48	3387-3390	3-T	_
15-49	3391-3398	Siemens	_
15-50	3399-3403	Trio	_
15-51	3404-3411	scanner	_
15-52	3412-3413	(	_
15-53	3414-3422	Erlangen	_
15-54	3423-3424	,	_
15-55	3425-3432	Germany	_
15-56	3433-3434	;	_
15-57	3435-3437	81	_
15-58	3438-3442	2-mm	_
15-59	3443-3448	axial	_
15-60	3449-3455	slices	_
15-61	3456-3457	;	_
15-62	3458-3461	128	_
15-63	3462-3463	×	_
15-64	3464-3467	128	_
15-65	3468-3474	matrix	_
15-66	3475-3476	;	_
15-67	3477-3480	FOV	_
15-68	3481-3482	=	_
15-69	3483-3485	22	_
15-70	3486-3487	×	_
15-71	3488-3490	22	_
15-72	3491-3493	cm	_
15-73	3494-3495	;	_
15-74	3496-3498	TR	_
15-75	3499-3500	=	_
15-76	3501-3502	2	_
15-77	3503-3504	s	_
15-78	3505-3506	;	_
15-79	3507-3510	see	_
15-80	3511-3524	Supplementary	_
15-81	3525-3532	Methods	_
15-82	3533-3536	for	_
15-83	3537-3547	additional	_
15-84	3548-3556	scanning	_
15-85	3557-3567	parameters	_
15-86	3568-3569	)	_
15-87	3570-3571	.	_

Text=Also, in each session, we acquired a whole-brain T1-weighted structural image (MPRAGE) for anatomical reference (1-mm3 isotropic voxels).
16-1	3572-3576	Also	_
16-2	3577-3578	,	_
16-3	3579-3581	in	_
16-4	3582-3586	each	_
16-5	3587-3594	session	_
16-6	3595-3596	,	_
16-7	3597-3599	we	_
16-8	3600-3608	acquired	_
16-9	3609-3610	a	_
16-10	3611-3622	whole-brain	_
16-11	3623-3634	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
16-12	3635-3645	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
16-13	3646-3651	image	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
16-14	3652-3653	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
16-15	3654-3660	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
16-16	3661-3662	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
16-17	3663-3666	for	_
16-18	3667-3677	anatomical	_
16-19	3678-3687	reference	_
16-20	3688-3689	(	_
16-21	3690-3695	1-mm3	_
16-22	3696-3705	isotropic	_
16-23	3706-3712	voxels	_
16-24	3713-3714	)	_
16-25	3715-3716	.	_

Text=Two patients were removed from subsequent analyses due to head motion sufficient to produce phase-instability in the functional images (resulting in the loss of entire runs to artifact).
17-1	3717-3720	Two	_
17-2	3721-3729	patients	_
17-3	3730-3734	were	_
17-4	3735-3742	removed	_
17-5	3743-3747	from	_
17-6	3748-3758	subsequent	_
17-7	3759-3767	analyses	_
17-8	3768-3771	due	_
17-9	3772-3774	to	_
17-10	3775-3779	head	_
17-11	3780-3786	motion	_
17-12	3787-3797	sufficient	_
17-13	3798-3800	to	_
17-14	3801-3808	produce	_
17-15	3809-3826	phase-instability	_
17-16	3827-3829	in	_
17-17	3830-3833	the	_
17-18	3834-3844	functional	_
17-19	3845-3851	images	_
17-20	3852-3853	(	_
17-21	3854-3863	resulting	_
17-22	3864-3866	in	_
17-23	3867-3870	the	_
17-24	3871-3875	loss	_
17-25	3876-3878	of	_
17-26	3879-3885	entire	_
17-27	3886-3890	runs	_
17-28	3891-3893	to	_
17-29	3894-3902	artifact	_
17-30	3903-3904	)	_
17-31	3905-3906	.	_

Text=One control was excluded from subsequent analyses, due to a lack of task-engagement (evidenced by random button-pressing and no attempt to learn).
18-1	3907-3910	One	_
18-2	3911-3918	control	_
18-3	3919-3922	was	_
18-4	3923-3931	excluded	_
18-5	3932-3936	from	_
18-6	3937-3947	subsequent	_
18-7	3948-3956	analyses	_
18-8	3957-3958	,	_
18-9	3959-3962	due	_
18-10	3963-3965	to	_
18-11	3966-3967	a	_
18-12	3968-3972	lack	_
18-13	3973-3975	of	_
18-14	3976-3991	task-engagement	_
18-15	3992-3993	(	_
18-16	3994-4003	evidenced	_
18-17	4004-4006	by	_
18-18	4007-4013	random	_
18-19	4014-4029	button-pressing	_
18-20	4030-4033	and	_
18-21	4034-4036	no	_
18-22	4037-4044	attempt	_
18-23	4045-4047	to	_
18-24	4048-4053	learn	_
18-25	4054-4055	)	_
18-26	4056-4057	.	_

Text=Analysis of Behavioral and Characterizing Data Groups did not differ in age, gender, race, and parental education (Table 1).
19-1	4058-4066	Analysis	_
19-2	4067-4069	of	_
19-3	4070-4080	Behavioral	_
19-4	4081-4084	and	_
19-5	4085-4099	Characterizing	_
19-6	4100-4104	Data	_
19-7	4105-4111	Groups	_
19-8	4112-4115	did	_
19-9	4116-4119	not	_
19-10	4120-4126	differ	_
19-11	4127-4129	in	_
19-12	4130-4133	age	_
19-13	4134-4135	,	_
19-14	4136-4142	gender	_
19-15	4143-4144	,	_
19-16	4145-4149	race	_
19-17	4150-4151	,	_
19-18	4152-4155	and	_
19-19	4156-4164	parental	_
19-20	4165-4174	education	_
19-21	4175-4176	(	_
19-22	4177-4182	Table	_
19-23	4183-4184	1	_
19-24	4185-4186	)	_
19-25	4187-4188	.	_

Text=As expected, significant between-group differences were observed for participant educational attainment and multiple measures of overall intellectual functioning.
20-1	4189-4191	As	_
20-2	4192-4200	expected	_
20-3	4201-4202	,	_
20-4	4203-4214	significant	_
20-5	4215-4228	between-group	_
20-6	4229-4240	differences	_
20-7	4241-4245	were	_
20-8	4246-4254	observed	_
20-9	4255-4258	for	_
20-10	4259-4270	participant	_
20-11	4271-4282	educational	_
20-12	4283-4293	attainment	_
20-13	4294-4297	and	_
20-14	4298-4306	multiple	_
20-15	4307-4315	measures	_
20-16	4316-4318	of	_
20-17	4319-4326	overall	_
20-18	4327-4339	intellectual	_
20-19	4340-4351	functioning	_
20-20	4352-4353	.	_

Text=Behavioral data were analyzed for the proportion of trials on which participants chose the optimal (more-frequently-reinforced) stimulus from a pair, as well as “ win-stay ” and “ lose-shift ” rates (see Supplementary Methods for details).
21-1	4354-4364	Behavioral	_
21-2	4365-4369	data	_
21-3	4370-4374	were	_
21-4	4375-4383	analyzed	_
21-5	4384-4387	for	_
21-6	4388-4391	the	_
21-7	4392-4402	proportion	_
21-8	4403-4405	of	_
21-9	4406-4412	trials	_
21-10	4413-4415	on	_
21-11	4416-4421	which	_
21-12	4422-4434	participants	_
21-13	4435-4440	chose	_
21-14	4441-4444	the	_
21-15	4445-4452	optimal	_
21-16	4453-4454	(	_
21-17	4455-4481	more-frequently-reinforced	_
21-18	4482-4483	)	_
21-19	4484-4492	stimulus	_
21-20	4493-4497	from	_
21-21	4498-4499	a	_
21-22	4500-4504	pair	_
21-23	4505-4506	,	_
21-24	4507-4509	as	_
21-25	4510-4514	well	_
21-26	4515-4517	as	_
21-27	4518-4519	“	_
21-28	4520-4528	win-stay	_
21-29	4529-4530	”	_
21-30	4531-4534	and	_
21-31	4535-4536	“	_
21-32	4537-4547	lose-shift	_
21-33	4548-4549	”	_
21-34	4550-4555	rates	_
21-35	4556-4557	(	_
21-36	4558-4561	see	_
21-37	4562-4575	Supplementary	_
21-38	4576-4583	Methods	_
21-39	4584-4587	for	_
21-40	4588-4595	details	_
21-41	4596-4597	)	_
21-42	4598-4599	.	_

Text=Finally, we used a computational model, similar to those previously used by our group, in order to estimate action values and prediction errors on a trial-wise basis.
22-1	4600-4607	Finally	_
22-2	4608-4609	,	_
22-3	4610-4612	we	_
22-4	4613-4617	used	_
22-5	4618-4619	a	_
22-6	4620-4633	computational	_
22-7	4634-4639	model	_
22-8	4640-4641	,	_
22-9	4642-4649	similar	_
22-10	4650-4652	to	_
22-11	4653-4658	those	_
22-12	4659-4669	previously	_
22-13	4670-4674	used	_
22-14	4675-4677	by	_
22-15	4678-4681	our	_
22-16	4682-4687	group	_
22-17	4688-4689	,	_
22-18	4690-4692	in	_
22-19	4693-4698	order	_
22-20	4699-4701	to	_
22-21	4702-4710	estimate	_
22-22	4711-4717	action	_
22-23	4718-4724	values	_
22-24	4725-4728	and	_
22-25	4729-4739	prediction	_
22-26	4740-4746	errors	_
22-27	4747-4749	on	_
22-28	4750-4751	a	_
22-29	4752-4762	trial-wise	_
22-30	4763-4768	basis	_
22-31	4769-4770	.	_

Text=Comparison of multiple models revealed that a Q-learning model with separate learning rates for positive and negative RPEs fit the behavioral data the best (see Supplementary Materials for details).
23-1	4771-4781	Comparison	_
23-2	4782-4784	of	_
23-3	4785-4793	multiple	_
23-4	4794-4800	models	_
23-5	4801-4809	revealed	_
23-6	4810-4814	that	_
23-7	4815-4816	a	_
23-8	4817-4827	Q-learning	_
23-9	4828-4833	model	_
23-10	4834-4838	with	_
23-11	4839-4847	separate	_
23-12	4848-4856	learning	_
23-13	4857-4862	rates	_
23-14	4863-4866	for	_
23-15	4867-4875	positive	_
23-16	4876-4879	and	_
23-17	4880-4888	negative	_
23-18	4889-4893	RPEs	_
23-19	4894-4897	fit	_
23-20	4898-4901	the	_
23-21	4902-4912	behavioral	_
23-22	4913-4917	data	_
23-23	4918-4921	the	_
23-24	4922-4926	best	_
23-25	4927-4928	(	_
23-26	4929-4932	see	_
23-27	4933-4946	Supplementary	_
23-28	4947-4956	Materials	_
23-29	4957-4960	for	_
23-30	4961-4968	details	_
23-31	4969-4970	)	_
23-32	4971-4972	.	_

Text=Analyses of Event-related fMRI Data Single-subject Analyses We performed two sets of regression analyses (general linear models, or GLMs) of single-subject voxel-wise time series, one with binary regressors corresponding to the six different trial types (three different pairs x two possible outcomes), and one using parametric regressors (see Supplementary Methods for details).
24-1	4973-4981	Analyses	_
24-2	4982-4984	of	_
24-3	4985-4998	Event-related	_
24-4	4999-5003	fMRI	_
24-5	5004-5008	Data	_
24-6	5009-5023	Single-subject	_
24-7	5024-5032	Analyses	_
24-8	5033-5035	We	_
24-9	5036-5045	performed	_
24-10	5046-5049	two	_
24-11	5050-5054	sets	_
24-12	5055-5057	of	_
24-13	5058-5068	regression	_
24-14	5069-5077	analyses	_
24-15	5078-5079	(	_
24-16	5080-5087	general	_
24-17	5088-5094	linear	_
24-18	5095-5101	models	_
24-19	5102-5103	,	_
24-20	5104-5106	or	_
24-21	5107-5111	GLMs	_
24-22	5112-5113	)	_
24-23	5114-5116	of	_
24-24	5117-5131	single-subject	_
24-25	5132-5142	voxel-wise	_
24-26	5143-5147	time	_
24-27	5148-5154	series	_
24-28	5155-5156	,	_
24-29	5157-5160	one	_
24-30	5161-5165	with	_
24-31	5166-5172	binary	_
24-32	5173-5183	regressors	_
24-33	5184-5197	corresponding	_
24-34	5198-5200	to	_
24-35	5201-5204	the	_
24-36	5205-5208	six	_
24-37	5209-5218	different	_
24-38	5219-5224	trial	_
24-39	5225-5230	types	_
24-40	5231-5232	(	_
24-41	5233-5238	three	_
24-42	5239-5248	different	_
24-43	5249-5254	pairs	_
24-44	5255-5256	x	_
24-45	5257-5260	two	_
24-46	5261-5269	possible	_
24-47	5270-5278	outcomes	_
24-48	5279-5280	)	_
24-49	5281-5282	,	_
24-50	5283-5286	and	_
24-51	5287-5290	one	_
24-52	5291-5296	using	_
24-53	5297-5307	parametric	_
24-54	5308-5318	regressors	_
24-55	5319-5320	(	_
24-56	5321-5324	see	_
24-57	5325-5338	Supplementary	_
24-58	5339-5346	Methods	_
24-59	5347-5350	for	_
24-60	5351-5358	details	_
24-61	5359-5360	)	_
24-62	5361-5362	.	_

Text=Binary regressors were 3-second boxcar functions, time-locked to the onset of individual trials and convolved with a model hemodynamic response function.
25-1	5363-5369	Binary	_
25-2	5370-5380	regressors	_
25-3	5381-5385	were	_
25-4	5386-5394	3-second	_
25-5	5395-5401	boxcar	_
25-6	5402-5411	functions	_
25-7	5412-5413	,	_
25-8	5414-5425	time-locked	_
25-9	5426-5428	to	_
25-10	5429-5432	the	_
25-11	5433-5438	onset	_
25-12	5439-5441	of	_
25-13	5442-5452	individual	_
25-14	5453-5459	trials	_
25-15	5460-5463	and	_
25-16	5464-5473	convolved	_
25-17	5474-5478	with	_
25-18	5479-5480	a	_
25-19	5481-5486	model	_
25-20	5487-5498	hemodynamic	_
25-21	5499-5507	response	_
25-22	5508-5516	function	_
25-23	5517-5518	.	_

Text=Parametric regressors were derived from the results of computational modeling of individual behavior, which allowed for the estimation of prediction errors on a trial-wise basis.
26-1	5519-5529	Parametric	_
26-2	5530-5540	regressors	_
26-3	5541-5545	were	_
26-4	5546-5553	derived	_
26-5	5554-5558	from	_
26-6	5559-5562	the	_
26-7	5563-5570	results	_
26-8	5571-5573	of	_
26-9	5574-5587	computational	_
26-10	5588-5596	modeling	_
26-11	5597-5599	of	_
26-12	5600-5610	individual	_
26-13	5611-5619	behavior	_
26-14	5620-5621	,	_
26-15	5622-5627	which	_
26-16	5628-5635	allowed	_
26-17	5636-5639	for	_
26-18	5640-5643	the	_
26-19	5644-5654	estimation	_
26-20	5655-5657	of	_
26-21	5658-5668	prediction	_
26-22	5669-5675	errors	_
26-23	5676-5678	on	_
26-24	5679-5680	a	_
26-25	5681-5691	trial-wise	_
26-26	5692-5697	basis	_
26-27	5698-5699	.	_

Text=Whole-brain Group-level Analyses To test for significant activations within groups, as well as for significant between-group differences in BOLD signal activations associated with parametric RPE regressors, we used whole-brain t-tests (AFNI 3dttest++ command).
27-1	5700-5711	Whole-brain	_
27-2	5712-5723	Group-level	_
27-3	5724-5732	Analyses	_
27-4	5733-5735	To	_
27-5	5736-5740	test	_
27-6	5741-5744	for	_
27-7	5745-5756	significant	_
27-8	5757-5768	activations	_
27-9	5769-5775	within	_
27-10	5776-5782	groups	_
27-11	5783-5784	,	_
27-12	5785-5787	as	_
27-13	5788-5792	well	_
27-14	5793-5795	as	_
27-15	5796-5799	for	_
27-16	5800-5811	significant	_
27-17	5812-5825	between-group	_
27-18	5826-5837	differences	_
27-19	5838-5840	in	_
27-20	5841-5845	BOLD	_
27-21	5846-5852	signal	_
27-22	5853-5864	activations	_
27-23	5865-5875	associated	_
27-24	5876-5880	with	_
27-25	5881-5891	parametric	_
27-26	5892-5895	RPE	_
27-27	5896-5906	regressors	_
27-28	5907-5908	,	_
27-29	5909-5911	we	_
27-30	5912-5916	used	_
27-31	5917-5928	whole-brain	_
27-32	5929-5936	t-tests	_
27-33	5937-5938	(	_
27-34	5939-5943	AFNI	_
27-35	5944-5953	3dttest++	_
27-36	5954-5961	command	_
27-37	5962-5963	)	_
27-38	5964-5965	.	_

Text=To test for significant within-group effects of outcome valence, we used whole-brain paired t-tests (AFNI 3dttest++ command).
28-1	5966-5968	To	_
28-2	5969-5973	test	_
28-3	5974-5977	for	_
28-4	5978-5989	significant	_
28-5	5990-6002	within-group	_
28-6	6003-6010	effects	_
28-7	6011-6013	of	_
28-8	6014-6021	outcome	_
28-9	6022-6029	valence	_
28-10	6030-6031	,	_
28-11	6032-6034	we	_
28-12	6035-6039	used	_
28-13	6040-6051	whole-brain	_
28-14	6052-6058	paired	_
28-15	6059-6066	t-tests	_
28-16	6067-6068	(	_
28-17	6069-6073	AFNI	_
28-18	6074-6083	3dttest++	_
28-19	6084-6091	command	_
28-20	6092-6093	)	_
28-21	6094-6095	.	_

Text=To test for significant between-group differences in BOLD signal contrasts with regard to experienced value and expected value, we used whole-brain multivariate models (AFNI 3dMVM command), with factors of group and value (6 levels of experienced value, 3 levels of expected value).
29-1	6096-6098	To	_
29-2	6099-6103	test	_
29-3	6104-6107	for	_
29-4	6108-6119	significant	_
29-5	6120-6133	between-group	_
29-6	6134-6145	differences	_
29-7	6146-6148	in	_
29-8	6149-6153	BOLD	_
29-9	6154-6160	signal	_
29-10	6161-6170	contrasts	_
29-11	6171-6175	with	_
29-12	6176-6182	regard	_
29-13	6183-6185	to	_
29-14	6186-6197	experienced	_
29-15	6198-6203	value	_
29-16	6204-6207	and	_
29-17	6208-6216	expected	_
29-18	6217-6222	value	_
29-19	6223-6224	,	_
29-20	6225-6227	we	_
29-21	6228-6232	used	_
29-22	6233-6244	whole-brain	_
29-23	6245-6257	multivariate	_
29-24	6258-6264	models	_
29-25	6265-6266	(	_
29-26	6267-6271	AFNI	_
29-27	6272-6277	3dMVM	_
29-28	6278-6285	command	_
29-29	6286-6287	)	_
29-30	6288-6289	,	_
29-31	6290-6294	with	_
29-32	6295-6302	factors	_
29-33	6303-6305	of	_
29-34	6306-6311	group	_
29-35	6312-6315	and	_
29-36	6316-6321	value	_
29-37	6322-6323	(	_
29-38	6324-6325	6	_
29-39	6326-6332	levels	_
29-40	6333-6335	of	_
29-41	6336-6347	experienced	_
29-42	6348-6353	value	_
29-43	6354-6355	,	_
29-44	6356-6357	3	_
29-45	6358-6364	levels	_
29-46	6365-6367	of	_
29-47	6368-6376	expected	_
29-48	6377-6382	value	_
29-49	6383-6384	)	_
29-50	6385-6386	.	_

Text=For whole-brain analyses, we used a voxel-wise threshold of p=0.001 and a cluster-size threshold of 95 voxels, determined by Monte Carlo simulations.
30-1	6387-6390	For	_
30-2	6391-6402	whole-brain	_
30-3	6403-6411	analyses	_
30-4	6412-6413	,	_
30-5	6414-6416	we	_
30-6	6417-6421	used	_
30-7	6422-6423	a	_
30-8	6424-6434	voxel-wise	_
30-9	6435-6444	threshold	_
30-10	6445-6447	of	_
30-11	6448-6455	p=0.001	_
30-12	6456-6459	and	_
30-13	6460-6461	a	_
30-14	6462-6474	cluster-size	_
30-15	6475-6484	threshold	_
30-16	6485-6487	of	_
30-17	6488-6490	95	_
30-18	6491-6497	voxels	_
30-19	6498-6499	,	_
30-20	6500-6510	determined	_
30-21	6511-6513	by	_
30-22	6514-6519	Monte	_
30-23	6520-6525	Carlo	_
30-24	6526-6537	simulations	_
30-25	6538-6539	.	_

Text=Analyses of event-related neural responses in regions-of-interest (ROIs) Based on the prior literature, we looked for effects of expected value valence, RPE valence, and outcome valence in VS (bilaterally), vmPFC/mOFC, dorsal anterior cingulate cortex (dACC), right anterior insula (R AI), and left anterior insula (L AI; see Figure 2A–C for specific coordinates of ROIs; see Supplementary Materials for justification of coordinates chosen).
31-1	6540-6548	Analyses	_
31-2	6549-6551	of	_
31-3	6552-6565	event-related	_
31-4	6566-6572	neural	_
31-5	6573-6582	responses	_
31-6	6583-6585	in	_
31-7	6586-6605	regions-of-interest	_
31-8	6606-6607	(	_
31-9	6608-6612	ROIs	_
31-10	6613-6614	)	_
31-11	6615-6620	Based	_
31-12	6621-6623	on	_
31-13	6624-6627	the	_
31-14	6628-6633	prior	_
31-15	6634-6644	literature	_
31-16	6645-6646	,	_
31-17	6647-6649	we	_
31-18	6650-6656	looked	_
31-19	6657-6660	for	_
31-20	6661-6668	effects	_
31-21	6669-6671	of	_
31-22	6672-6680	expected	_
31-23	6681-6686	value	_
31-24	6687-6694	valence	_
31-25	6695-6696	,	_
31-26	6697-6700	RPE	_
31-27	6701-6708	valence	_
31-28	6709-6710	,	_
31-29	6711-6714	and	_
31-30	6715-6722	outcome	_
31-31	6723-6730	valence	_
31-32	6731-6733	in	_
31-33	6734-6736	VS	_
31-34	6737-6738	(	_
31-35	6739-6750	bilaterally	_
31-36	6751-6752	)	_
31-37	6753-6754	,	_
31-38	6755-6765	vmPFC/mOFC	_
31-39	6766-6767	,	_
31-40	6768-6774	dorsal	_
31-41	6775-6783	anterior	_
31-42	6784-6793	cingulate	_
31-43	6794-6800	cortex	_
31-44	6801-6802	(	_
31-45	6803-6807	dACC	_
31-46	6808-6809	)	_
31-47	6810-6811	,	_
31-48	6812-6817	right	_
31-49	6818-6826	anterior	_
31-50	6827-6833	insula	_
31-51	6834-6835	(	_
31-52	6836-6837	R	_
31-53	6838-6840	AI	_
31-54	6841-6842	)	_
31-55	6843-6844	,	_
31-56	6845-6848	and	_
31-57	6849-6853	left	_
31-58	6854-6862	anterior	_
31-59	6863-6869	insula	_
31-60	6870-6871	(	_
31-61	6872-6873	L	_
31-62	6874-6876	AI	_
31-63	6877-6878	;	_
31-64	6879-6882	see	_
31-65	6883-6889	Figure	_
31-66	6890-6894	2A–C	_
31-67	6895-6898	for	_
31-68	6899-6907	specific	_
31-69	6908-6919	coordinates	_
31-70	6920-6922	of	_
31-71	6923-6927	ROIs	_
31-72	6928-6929	;	_
31-73	6930-6933	see	_
31-74	6934-6947	Supplementary	_
31-75	6948-6957	Materials	_
31-76	6958-6961	for	_
31-77	6962-6975	justification	_
31-78	6976-6978	of	_
31-79	6979-6990	coordinates	_
31-80	6991-6997	chosen	_
31-81	6998-6999	)	_
31-82	7000-7001	.	_

Text=For the VS, we centered spheres of 5-mm radius on (±10, 8, −4) to form a single, bilateral ROI.
32-1	7002-7005	For	_
32-2	7006-7009	the	_
32-3	7010-7012	VS	_
32-4	7013-7014	,	_
32-5	7015-7017	we	_
32-6	7018-7026	centered	_
32-7	7027-7034	spheres	_
32-8	7035-7037	of	_
32-9	7038-7042	5-mm	_
32-10	7043-7049	radius	_
32-11	7050-7052	on	_
32-12	7053-7054	(	_
32-13	7055-7058	±10	_
32-14	7059-7060	,	_
32-15	7061-7062	8	_
32-16	7063-7064	,	_
32-17	7065-7067	−4	_
32-18	7068-7069	)	_
32-19	7070-7072	to	_
32-20	7073-7077	form	_
32-21	7078-7079	a	_
32-22	7080-7086	single	_
32-23	7087-7088	,	_
32-24	7089-7098	bilateral	_
32-25	7099-7102	ROI	_
32-26	7103-7104	.	_

Text=All ROIs in PFC consisted of spheres of 10-mm radius.
33-1	7105-7108	All	_
33-2	7109-7113	ROIs	_
33-3	7114-7116	in	_
33-4	7117-7120	PFC	_
33-5	7121-7130	consisted	_
33-6	7131-7133	of	_
33-7	7134-7141	spheres	_
33-8	7142-7144	of	_
33-9	7145-7150	10-mm	_
33-10	7151-7157	radius	_
33-11	7158-7159	.	_

Text=Our primary focus was on contrasts between outcomes of different objective values for the same RPE valence (e.g., Gain vs. Loss-avoidance, Miss vs. Loss).
34-1	7160-7163	Our	_
34-2	7164-7171	primary	_
34-3	7172-7177	focus	_
34-4	7178-7181	was	_
34-5	7182-7184	on	_
34-6	7185-7194	contrasts	_
34-7	7195-7202	between	_
34-8	7203-7211	outcomes	_
34-9	7212-7214	of	_
34-10	7215-7224	different	_
34-11	7225-7234	objective	_
34-12	7235-7241	values	_
34-13	7242-7245	for	_
34-14	7246-7249	the	_
34-15	7250-7254	same	_
34-16	7255-7258	RPE	_
34-17	7259-7266	valence	_
34-18	7267-7268	(	_
34-19	7269-7273	e.g.	_
34-20	7274-7275	,	_
34-21	7276-7280	Gain	_
34-22	7281-7284	vs.	_
34-23	7285-7299	Loss-avoidance	_
34-24	7300-7301	,	_
34-25	7302-7306	Miss	_
34-26	7307-7310	vs.	_
34-27	7311-7315	Loss	_
34-28	7316-7317	)	_
34-29	7318-7319	.	_

Text=Exploratory analyses examined contrasts between expected outcomes, corresponding to condition (e.g., Gain/Miss vs. Loss/Loss-avoidance).
35-1	7320-7331	Exploratory	_
35-2	7332-7340	analyses	_
35-3	7341-7349	examined	_
35-4	7350-7359	contrasts	_
35-5	7360-7367	between	_
35-6	7368-7376	expected	_
35-7	7377-7385	outcomes	_
35-8	7386-7387	,	_
35-9	7388-7401	corresponding	_
35-10	7402-7404	to	_
35-11	7405-7414	condition	_
35-12	7415-7416	(	_
35-13	7417-7421	e.g.	_
35-14	7422-7423	,	_
35-15	7424-7433	Gain/Miss	_
35-16	7434-7437	vs.	_
35-17	7438-7457	Loss/Loss-avoidance	_
35-18	7458-7459	)	_
35-19	7460-7461	.	_

Text=For each of these contrasts, we performed the following tests: 1) a repeated-measures ANOVA, within the control group, with ROI as a factor, in order to determine if the contrast differed from zero in the control group, without respect to ROI, and if the contrast differed as a function of ROI; 2) a repeated-measures ANOVA, across the entire sample, with group and ROI as factors, in order to determine if there was a between-group difference in the contrast, without respect to ROI, or a significant group x ROI interaction; 3) Spearman correlation analyses, between MRI contrasts in ROIs and RL performance measures in controls; and 4) Spearman correlation analyses, between MRI contrasts in ROIs and measures of motivational deficits in patients.
36-1	7462-7465	For	_
36-2	7466-7470	each	_
36-3	7471-7473	of	_
36-4	7474-7479	these	_
36-5	7480-7489	contrasts	_
36-6	7490-7491	,	_
36-7	7492-7494	we	_
36-8	7495-7504	performed	_
36-9	7505-7508	the	_
36-10	7509-7518	following	_
36-11	7519-7524	tests	_
36-12	7525-7526	:	_
36-13	7527-7528	1	_
36-14	7529-7530	)	_
36-15	7531-7532	a	_
36-16	7533-7550	repeated-measures	_
36-17	7551-7556	ANOVA	_
36-18	7557-7558	,	_
36-19	7559-7565	within	_
36-20	7566-7569	the	_
36-21	7570-7577	control	_
36-22	7578-7583	group	_
36-23	7584-7585	,	_
36-24	7586-7590	with	_
36-25	7591-7594	ROI	_
36-26	7595-7597	as	_
36-27	7598-7599	a	_
36-28	7600-7606	factor	_
36-29	7607-7608	,	_
36-30	7609-7611	in	_
36-31	7612-7617	order	_
36-32	7618-7620	to	_
36-33	7621-7630	determine	_
36-34	7631-7633	if	_
36-35	7634-7637	the	_
36-36	7638-7646	contrast	_
36-37	7647-7655	differed	_
36-38	7656-7660	from	_
36-39	7661-7665	zero	_
36-40	7666-7668	in	_
36-41	7669-7672	the	_
36-42	7673-7680	control	_
36-43	7681-7686	group	_
36-44	7687-7688	,	_
36-45	7689-7696	without	_
36-46	7697-7704	respect	_
36-47	7705-7707	to	_
36-48	7708-7711	ROI	_
36-49	7712-7713	,	_
36-50	7714-7717	and	_
36-51	7718-7720	if	_
36-52	7721-7724	the	_
36-53	7725-7733	contrast	_
36-54	7734-7742	differed	_
36-55	7743-7745	as	_
36-56	7746-7747	a	_
36-57	7748-7756	function	_
36-58	7757-7759	of	_
36-59	7760-7763	ROI	_
36-60	7764-7765	;	_
36-61	7766-7767	2	_
36-62	7768-7769	)	_
36-63	7770-7771	a	_
36-64	7772-7789	repeated-measures	_
36-65	7790-7795	ANOVA	_
36-66	7796-7797	,	_
36-67	7798-7804	across	_
36-68	7805-7808	the	_
36-69	7809-7815	entire	_
36-70	7816-7822	sample	_
36-71	7823-7824	,	_
36-72	7825-7829	with	_
36-73	7830-7835	group	_
36-74	7836-7839	and	_
36-75	7840-7843	ROI	_
36-76	7844-7846	as	_
36-77	7847-7854	factors	_
36-78	7855-7856	,	_
36-79	7857-7859	in	_
36-80	7860-7865	order	_
36-81	7866-7868	to	_
36-82	7869-7878	determine	_
36-83	7879-7881	if	_
36-84	7882-7887	there	_
36-85	7888-7891	was	_
36-86	7892-7893	a	_
36-87	7894-7907	between-group	_
36-88	7908-7918	difference	_
36-89	7919-7921	in	_
36-90	7922-7925	the	_
36-91	7926-7934	contrast	_
36-92	7935-7936	,	_
36-93	7937-7944	without	_
36-94	7945-7952	respect	_
36-95	7953-7955	to	_
36-96	7956-7959	ROI	_
36-97	7960-7961	,	_
36-98	7962-7964	or	_
36-99	7965-7966	a	_
36-100	7967-7978	significant	_
36-101	7979-7984	group	_
36-102	7985-7986	x	_
36-103	7987-7990	ROI	_
36-104	7991-8002	interaction	_
36-105	8003-8004	;	_
36-106	8005-8006	3	_
36-107	8007-8008	)	_
36-108	8009-8017	Spearman	_
36-109	8018-8029	correlation	_
36-110	8030-8038	analyses	_
36-111	8039-8040	,	_
36-112	8041-8048	between	_
36-113	8049-8052	MRI	_
36-114	8053-8062	contrasts	_
36-115	8063-8065	in	_
36-116	8066-8070	ROIs	_
36-117	8071-8074	and	_
36-118	8075-8077	RL	_
36-119	8078-8089	performance	_
36-120	8090-8098	measures	_
36-121	8099-8101	in	_
36-122	8102-8110	controls	_
36-123	8111-8112	;	_
36-124	8113-8116	and	_
36-125	8117-8118	4	_
36-126	8119-8120	)	_
36-127	8121-8129	Spearman	_
36-128	8130-8141	correlation	_
36-129	8142-8150	analyses	_
36-130	8151-8152	,	_
36-131	8153-8160	between	_
36-132	8161-8164	MRI	_
36-133	8165-8174	contrasts	_
36-134	8175-8177	in	_
36-135	8178-8182	ROIs	_
36-136	8183-8186	and	_
36-137	8187-8195	measures	_
36-138	8196-8198	of	_
36-139	8199-8211	motivational	_
36-140	8212-8220	deficits	_
36-141	8221-8223	in	_
36-142	8224-8232	patients	_
36-143	8233-8234	.	_

Text=In order to quantify motivational deficits in patients, we computed an avolition/anhedonia factor score by averaging item scores from the avolition/role-functioning and anhedonia/asociality subscales of the SANS.
37-1	8235-8237	In	_
37-2	8238-8243	order	_
37-3	8244-8246	to	_
37-4	8247-8255	quantify	_
37-5	8256-8268	motivational	_
37-6	8269-8277	deficits	_
37-7	8278-8280	in	_
37-8	8281-8289	patients	_
37-9	8290-8291	,	_
37-10	8292-8294	we	_
37-11	8295-8303	computed	_
37-12	8304-8306	an	_
37-13	8307-8326	avolition/anhedonia	_
37-14	8327-8333	factor	_
37-15	8334-8339	score	_
37-16	8340-8342	by	_
37-17	8343-8352	averaging	_
37-18	8353-8357	item	_
37-19	8358-8364	scores	_
37-20	8365-8369	from	_
37-21	8370-8373	the	_
37-22	8374-8400	avolition/role-functioning	_
37-23	8401-8404	and	_
37-24	8405-8425	anhedonia/asociality	_
37-25	8426-8435	subscales	_
37-26	8436-8438	of	_
37-27	8439-8442	the	_
37-28	8443-8447	SANS	_
37-29	8448-8449	.	_

Text=In order to determine whether measures of motivational deficits in patients were related specifically to negative symptoms, rather than measures in multiple symptom classes, as well as cognitive domains, we also performed Spearman correlation analyses, between MRI contrasts in ROIs and 1) individual psychosis scores, by averaging ratings from individual psychosis items on the BPRS (Suspiciousness, Grandiosity, Hallucinations, and Unusual Thought Content), 2) individual IQ estimates, as well as several measures of intellectual function from the MATRICS battery, and 3) standardized APD doses for SZ patients (see Supplementary Materials for conversions and results of correlation analyses).
38-1	8450-8452	In	_
38-2	8453-8458	order	_
38-3	8459-8461	to	_
38-4	8462-8471	determine	_
38-5	8472-8479	whether	_
38-6	8480-8488	measures	_
38-7	8489-8491	of	_
38-8	8492-8504	motivational	_
38-9	8505-8513	deficits	_
38-10	8514-8516	in	_
38-11	8517-8525	patients	_
38-12	8526-8530	were	_
38-13	8531-8538	related	_
38-14	8539-8551	specifically	_
38-15	8552-8554	to	_
38-16	8555-8563	negative	_
38-17	8564-8572	symptoms	_
38-18	8573-8574	,	_
38-19	8575-8581	rather	_
38-20	8582-8586	than	_
38-21	8587-8595	measures	_
38-22	8596-8598	in	_
38-23	8599-8607	multiple	_
38-24	8608-8615	symptom	_
38-25	8616-8623	classes	_
38-26	8624-8625	,	_
38-27	8626-8628	as	_
38-28	8629-8633	well	_
38-29	8634-8636	as	_
38-30	8637-8646	cognitive	_
38-31	8647-8654	domains	_
38-32	8655-8656	,	_
38-33	8657-8659	we	_
38-34	8660-8664	also	_
38-35	8665-8674	performed	_
38-36	8675-8683	Spearman	_
38-37	8684-8695	correlation	_
38-38	8696-8704	analyses	_
38-39	8705-8706	,	_
38-40	8707-8714	between	_
38-41	8715-8718	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
38-42	8719-8728	contrasts	_
38-43	8729-8731	in	_
38-44	8732-8736	ROIs	_
38-45	8737-8740	and	_
38-46	8741-8742	1	_
38-47	8743-8744	)	_
38-48	8745-8755	individual	_
38-49	8756-8765	psychosis	_
38-50	8766-8772	scores	_
38-51	8773-8774	,	_
38-52	8775-8777	by	_
38-53	8778-8787	averaging	_
38-54	8788-8795	ratings	_
38-55	8796-8800	from	_
38-56	8801-8811	individual	_
38-57	8812-8821	psychosis	_
38-58	8822-8827	items	_
38-59	8828-8830	on	_
38-60	8831-8834	the	_
38-61	8835-8839	BPRS	_
38-62	8840-8841	(	_
38-63	8842-8856	Suspiciousness	_
38-64	8857-8858	,	_
38-65	8859-8870	Grandiosity	_
38-66	8871-8872	,	_
38-67	8873-8887	Hallucinations	_
38-68	8888-8889	,	_
38-69	8890-8893	and	_
38-70	8894-8901	Unusual	_
38-71	8902-8909	Thought	_
38-72	8910-8917	Content	_
38-73	8918-8919	)	_
38-74	8920-8921	,	_
38-75	8922-8923	2	_
38-76	8924-8925	)	_
38-77	8926-8936	individual	_
38-78	8937-8939	IQ	_
38-79	8940-8949	estimates	_
38-80	8950-8951	,	_
38-81	8952-8954	as	_
38-82	8955-8959	well	_
38-83	8960-8962	as	_
38-84	8963-8970	several	_
38-85	8971-8979	measures	_
38-86	8980-8982	of	_
38-87	8983-8995	intellectual	_
38-88	8996-9004	function	_
38-89	9005-9009	from	_
38-90	9010-9013	the	_
38-91	9014-9021	MATRICS	_
38-92	9022-9029	battery	_
38-93	9030-9031	,	_
38-94	9032-9035	and	_
38-95	9036-9037	3	_
38-96	9038-9039	)	_
38-97	9040-9052	standardized	_
38-98	9053-9056	APD	_
38-99	9057-9062	doses	_
38-100	9063-9066	for	_
38-101	9067-9069	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
38-102	9070-9078	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
38-103	9079-9080	(	_
38-104	9081-9084	see	_
38-105	9085-9098	Supplementary	_
38-106	9099-9108	Materials	_
38-107	9109-9112	for	_
38-108	9113-9124	conversions	_
38-109	9125-9128	and	_
38-110	9129-9136	results	_
38-111	9137-9139	of	_
38-112	9140-9151	correlation	_
38-113	9152-9160	analyses	_
38-114	9161-9162	)	_
38-115	9163-9164	.	_

